SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation announced that the Fred Hutchinson Cancer Research Center (FHCRC) has purchased the BioMark™ system as a front-line technology for early detection and monitoring of cancers. The system represents a revolutionary advance for cancer research because of its nanofluidic chips, known as dynamic arrays and digital arrays, which miniaturize and integrate PCR assays at unmatched reaction density.
